SCHEDULE: Two Seas Capital Discloses 6.4% Stake in Avadel Pharma

Two Seas Capital LP, along with its general partner and chief investment officer, reported a 6.4% beneficial ownership stake in Avadel Pharmaceuticals plc.

Summary

• Two Seas Capital LP, Two Seas Capital GP LLC, and Sina Toussi (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G.
• The filing discloses beneficial ownership of 6,155,074 Ordinary Shares of Avadel Pharmaceuticals plc.
• This ownership represents 6.4% of the outstanding class of securities.
• The shares are held by Two Seas Global (Master) Fund LP, for which Two Seas Capital LP serves as investment manager.
• The percentage is calculated based on 96,777,000 shares outstanding as of June 30, 2025, as disclosed in Avadel Pharmaceuticals plc's Form 10-Q filed on August 7, 2025.
• The Reporting Persons have sole voting and sole dispositive power over the 6,155,074 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The filing is a standard beneficial ownership disclosure (Schedule 13G) indicating a passive investment. It does not contain information that would inherently suggest positive or negative sentiment regarding the company's performance or outlook.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the issuer's future operations or financial performance. It solely pertains to beneficial ownership disclosure.

Industry Context

This filing indicates a significant passive investment by Two Seas Capital in Avadel Pharmaceuticals, a company operating in the pharmaceutical sector. Such disclosures are common for institutional investors accumulating stakes in publicly traded companies, reflecting a belief in the company's long-term value without necessarily signaling an intent to influence management or strategy.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may be viewed positively by some shareholders as a vote of confidence, while others might monitor for potential future activist intentions, though none are stated here.

Key Dates

Keywords

Avadel Pharmaceuticals, Two Seas Capital, Beneficial Ownership, Schedule 13G, Pharmaceuticals, Investment, Shareholding, SEC Filing